Barbara Dalton, PhD, Vice President, Venture Capital and Worldwide Business Development, Pfizer Inc

Barbara is a pharmaceutical executive who has spent over 25years in the industry - most of that time as a corporate venture capitalist. At Pfizer she is responsible for growing their corporate venture activities, managing the current equity portfolio and advising on structured equity transactions. She was trained as a research scientist in a virology and immunology laboratory at The Medical College of Pennsylvania where she received her Ph.D. She pursued inflammation drug discovery research at SmithKline's research laboratories and joined their venture capital group, S.R. One, Limited in the early 1990's. While there, Barbara was a founding member of EuclidSR Partners, a private New York based venture capital firm where SmithKline (now GSK) was a leading limited partner. She joined that firm full time in 2003. In 2007 she moved to her current position at Pfizer. Barbara has managed over 20 fund investments and 60 diverse company investments in the US and Europe and has had direct investing responsibility for biotechnology therapeutic and platform technology companies, as well as some healthcare IT and service businesses. She has routinely represented her firms investments by participating at the board level in companies such as: Alere, Ciphergen, Corixa, Genset, Gliatech, Gryphon, Lexicon, iJET, OGS, Third Wave, Rib-X. In the community she has been active in her regional venture investors association, the MAC Alliance, serving as Chairman, and supported the venture philanthropy efforts of the Institute for the Study of Ageing as a board member. She is an advisor to the Dean of the Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors. She is also a member of the board of the New York Biotech Association and the National Venture Capital Association.

back to top

Frank Dinucci, President and CEO, Boston BioCom

Mr. Dinucci has a 35-year career that includes venture capital and merchant banking, institutional investment and investment banking. He most currently served as President and Executive Director of Connecticut Innovations, the quasi-governmental venture fund of the State of Connecticut charged with investing in early healthcare and other technology companies. As such, he managed a staff of about 40 people, all of which functioned to make investments in and oversee the development of young technology companies. Prior to CI, he was a managing director of SAE Ventures/Forest Street Capital where he spent fourteen years as an investor and advisor to early stage healthcare and technology companies, assisting them in a full range of formative stage issues. Prior experience includes thirteen years as an investment banker, principally at Merrill Lynch. He headed investment banking at Conning & Co. where he worked with private equity companies in addition to an extensive array of public companies. He has a broad background in the full range of financial products and services. He began his career with seven years as an institutional investment officer at Aetna Life & Casualty and Connecticut Bank & Trust managing large private and public portfolios. Prior to the formation of Boston BioCom, Mr. Dinucci served as the financial advisor to the MGH Russia team.

back to top

Frederick Frank, Vice Chairman, Peter J. Solomon

Frederick Frank is Vice Chairman of Peter J. Solomon Company. Before joining Peter J. Solomon Company Mr. Frank was Vice Chairman of Lehman Brothers and Barclays Capital. Before joining Lehman Brothers as a Partner in October, 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Incorporated. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts.

Born in Salt Lake City on May 31, 1932, Mr. Frank graduated from the Hotchkiss School in 1950 and from Yale University in 1954. He then spent two years in the Army, most of the time stationed with Supreme Headquarters Allied Powers Europe (SHAPE) in Paris. After release from service, he attended Stanford Graduate School of Business Administration. He received his MBA from Stanford in 1958 and began his Wall Street career that year. He also has a CFA Degree.

Mr. Frank is a Director of Landec Corporation; PDL BioPharma, Institute for Systems Biology; and Pharmaceutical Product Development, Inc. He is Chairman of the National Genetics Foundation; a past director of the Salk Institute; a member of the Yale School of Organization and Management Advisory Board, a member of the Pharmaceutical Executive Magazine advisory board and The Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a member of the Advisory Board of The Harvard School of Public Health and also a past member of the Advisory Board of the John's Hopkin's Bloomberg School of Public Health, and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation and Burrill and Co. He is past President of the Board of the The Hotchkiss School, and currently serves as a Trustee Emeritus.

Mr. Frank was honored for Outstanding Contributions in the Field of Immunology in 1998 by the Irvington Institute for Immunological Research, and, in 1997, he received the Biotech Meeting at Laguna Niguel Hall of Fame Award for Special Recognition for an Individual. He received The Albert Einstein Award from the Weizmann Institute of Science in 2004, the 2006 Gilda's Club of New York City Visionary Award and was selected The Top 100 Living Contributors to Biotechnology by Reed Elsevier and in 2007 he received the Award for Excellence from the American Liver Foundation.

Mr. Frank has provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare service providers, medical device and nutraceutical industries, and has been involved in hundreds of financings and merger and acquisition transactions in the global health care industry.

back to top

Jay Pieper, Chairman, Partners International, Vice President Corporate Development and Treasury, Partners HealthCare

Jay B. Pieper is Vice President for Corporate Development and Treasury Affairs of Partners HealthCare System, Inc. with a focus on financial strategy, investments, mergers and acquisitions, international programs, and various new business developments. He is also President and Chief Executive Officer of Partners International Medical Services LLC and Chairman of the Board of Partners Harvard Medical International. Mr. Pieper is a Director of Eclipsys Corporation, a healthcare information systems company; WorldCare, Inc., a global telemedicine company; CRICO, the Harvard captive professional liability insurer; and the Harvard Clinical Research Institute which supports clinical trials at several Harvard affiliates. He is a past Director of Biopure Corporation, a pharmaceutical company. He is a member and past director of the Financial Executives International. Mr. Pieper earned a BA from Cornell College in Mount Vernon, Iowa and an MBA from Washington University in St. Louis, Missouri.

back to top

Charles Sanders, MD, Former Chairman and CEO, Glaxo Inc. Former Executive Director, Massachusetts General Hospital

Charles A. Sanders, M.D., is the former chairman and CEO of Glaxo Inc., as well as a former member of the board of Glaxo plc.

Before joining Glaxo Inc. Dr. Sanders spent eight years with Squibb Corp., where he held a number of posts, including the position of vice chairman. He also served as chief executive officer of the science and technology group and chairman of the Science and Technology committee of the Board. Previously Dr. Sanders was general director of Massachusetts General Hospital and professor of medicine at Harvard Medical School. A native of Dallas, he is a graduate of Southwestern Medical College of the University of Texas.

Dr. Sanders is past chairman of the New York Academy of Sciences. He is currently a member of the Institute of Medicine of the National Academy of Sciences and past chairman of The Commonwealth Fund. His is also chairman of Project HOPE, the Foundation for the National Institutes of Health, and the UNC Health Care System. In addition, he serves on the boards of several publicly traded companies.

He and his wife, Ann, have four grown children and live in Durham, N.C.

back to top